greeksoup/ stock research
Stock research / United States / TEVA / Documents

Teva Pharmaceutical Industries Ltd. documents

Teva Pharmaceutical Industries (TEVA) annual report: the 10-K filed 3 February 2026 for the year ended 31 December 2025. Proxy statement (DEF 14A) filed 31 March 2026; latest 10-Q filed 3 November 2026 for the quarter ended 30 September 2026. Each links to the document on EDGAR, with 5 earnings press releases.

Earnings press releases (exhibit 99 to each results 8-K)

FiledDocumentOpenWhere
3 November 2026Results press release, exhibit 99 to the 8-K filed 3 November 2026The releaseEDGAR folder
29 July 2026Results press release, exhibit 99 to the 8-K filed 29 July 2026The releaseEDGAR folder
29 April 2026Results press release, exhibit 99 to the 8-K filed 29 April 2026The releaseEDGAR folder
28 January 2026Results press release, exhibit 99 to the 8-K filed 28 January 2026The releaseEDGAR folder
12 January 2026Results press release, exhibit 99 to the 8-K filed 12 January 2026The releaseEDGAR folder

Annual reports (10-K)

FiledDocumentOpenWhere
3 February 202610-K, period ended 31 December 2025The documentEDGAR folder

Quarterly reports (10-Q)

FiledDocumentOpenWhere
3 November 202610-Q, period ended 30 September 2026The documentEDGAR folder
29 July 202610-Q, period ended 30 June 2026The documentEDGAR folder
29 April 202610-Q, period ended 31 March 2026The documentEDGAR folder

Proxy statements

FiledDocumentOpenWhere
31 March 2026DEF 14A, period ended 28 May 2026The documentEDGAR folder

Annual report to shareholders

FiledDocumentOpenWhere
31 March 2026ARS, period ended 31 December 2025The documentEDGAR folder